CytomX Therapeutics, Inc. (6C1.F)
| Previous close | 1.4960 |
| Open | 1.4680 |
| Bid | 1.4890 x 200000 |
| Ask | 1.5290 x 200000 |
| Day's range | 1.4680 - 1.4680 |
| 52-week range | 0.9760 - 2.5050 |
| Volume | |
| Avg. volume | 240 |
| Market cap | 100.389M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.14 |
Simply Wall St.Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireCytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across ma
- GlobeNewswire
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milest
